June 2, 2025 4:44pm
The American Society of Clinical Oncology (ASCO) kicks-off its annual meeting in Chicago this week, with all eyes on the latest clinical developments in our universe – expect some clinical news flow!
News: BioNTech (BNTX +$17.29 or +18.05% to $113.10) after Bristol Myers Squibb (BMY +$0.51 or +1.06% to $48.79) agreed to a multibillion-dollar deal to be a partner to co-develop an experimental cancer drug. Moderna (MRNA +$0.49 or +1.84% to $27.05) on the back of the FDA approval of its next-generation Covid vaccine for adults 65 and older.
Blueprint Medicines (BPMC +$26.44 or +26.09% to $127.70) agreed to be acquired by Sanofi (SAN) expanding immunology offerings. Sanofi (SAN) committed to pay $129.00 per share in cash at close. BPMC shareholders will obtain a non-tradeable contingent value right (CVR), which could lead to further payments based on future milestones for BLU-808. The total value, inclusive of potential CVR payments, could reach $9.5bn. The offer price indicates a 27% premium on BPMC's closing price as of 5/30/25, and a 34% premium over the 30-day volume-weighted average price (VWAP).
Always be vigilant and in-the-know concerning your portfolio … why you need RMi!
Never leave an investor uninformed!
On point, short on words, long on facts and being judicious!
My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.
I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.
Monday, RegMed Investors’ (RMi) pre-open: A new ‘be month begins … https://www.regmedinvestors.com/articles/13941
Friday night’s RegMed Investors (RMi) Closing Bell: the blessing and curses … https://www.regmedinvestors.com/articles/13940
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812
Monday: The Dow closed UP +35.41points or +0.08%, the S&P closed UP +24.25 points or +0.41% while the Nasdaq closed UP +128.85 points or +0.67%
- The Dow, Nasdaq and S&P sputter as EU and China trade tensions increased
Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies
- Factory activity in the U.S. remained in contraction during May while construction spending (-0.4% from previous -0.7%) unexpectedly declined. The ISM manufacturing index posted a reading of 48.5 and 0.2% point below April. As the index measures the %of companies seeing expansion, anything below 50% represents contraction.
Monday’s advance/decline line opened with a positive 20 incliner, 11 decline and 4 flats ending with a positive close of 25 incliners, 7 decliners and 3 flats
Metrics: Monday, the IBB was up +1.99%, the XBI was up +2.05% while the VIX was down -0.18 points or -0.97% at 18.39
Q2/25 – June - 1 positive close
- May – 1 market holiday, 10 negative and 11 positive closes
- April – 11 positive and 10 negative closes
Mondays Closing UP (10 of 25)
- Blueprint Medicine (BPMC +$26.44 after Friday’s -$1.71
- Ultragenyx Pharmaceuticals (RARE +$2.11 after Friday’s -$1.00),
- Alnylam Pharmaceuticals (ALNY +$1.53 after Friday +$11.66),
- Regenxbio (RGNX +$1.50),
- CRISPR Therapeutics (CRSP +$0.66 after Friday’s -$0.49),
- Agenus (AGEN +$0.07 after Friday’s +$0.23),
- CRISPR Therapeutics (CRSP +$0.65)
- Ionis Pharmaceuticals (IONS +$0.60 after Friday’s +$0.05),
- Voyager Therapeutics (VYGR +$0.55),
- Moderna (MRNA +$0.49 after Friday’s -$0.37),
Flat (3)
- bluebird bio (BLUE)
- Harvard Apparatus RT (OTCQB: HRGN)
- Homology Medicine (FIXX)
Monday’s Closing DOWN (7 of 7):
- BioLife Solutions (BLFS -$1.19 after Friday -$0.44),
- Vericel (VCEL -$0.83),
- Mesoblast (MESO -$0.26),
- Caribou Biosciences (CRBU -$0.0851),
- Lenz Therapeutics (LENZ -$0.04 after Friday -$0.33),
- MiMedx (MDXG -$0.04),
- Brainstorm Cell Therapeutics (BCLI -$0.01 after Friday’s $0.00),
The BOTTOM LINE: The cell and gene therapy sector jumped after its napping in the May share pricing doldrums with a sweetener of BPMC getting an acquired by BMY.
In addition to what I wrote this a.m., sell in May' strategy didn't pay off as alternation – positive versus negative sector closes - seemed to be the key.
As I also wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble! Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”
Although historically, June has been a slow or weak month – we just saw a tremendous start (6/2) with partnership, acquisition and regulatory news – also ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.
There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.
June ‘25: understand the “flow” …
- 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats
From the last week of May:
- 5/30 – Friday closed negative with 6 positive, 26 negative and 3 flats
- 5/29 – Thursday closed positive with 24 positive, 10 negative and 1 flat
- 5/28 – Wednesday’s closed negative with 7 positive, 26 negative and 2 flats
- 5/27 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
- 5/26 – Monday market holiday
I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.
- What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.”
- Algos and electronic trading, can’t do with them and can’t do without them <me>
“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
- If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
Why do I keep repeating, so investors can make the connection …
The top three (3) performing in the session:
- Monday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Alnylam Pharmaceuticals (ALNY)
- Friday: Alnylam Pharmaceuticals (ALNY), Agenus (AGEN) and Harvard Apparatus RT (OTCQB: HRGN)
The worst three (3) in the session:
- Monday: BioLife Solutions (BLFS), Vericel (VCEL) and Mesoblast (MESO)
- Friday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Intellia Therapeutics (NTLA)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
